Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.16NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.16NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.16NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.16NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.16NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-14622Hong Kong
BA.2.16ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.9.4ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.9.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.9.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.9.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.9.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.9.4NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.9.4NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.9.4ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.55ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.55ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.55NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.55NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.55NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.55NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.55NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.55ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.39ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.39ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.39NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.39NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.39NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.39NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.39NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.39ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.64ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.64ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.64NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.64NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.64NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.64NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.64NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.64ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
AY.8 (Delta)ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
AY.8 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
AY.8 (Delta)NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-21977.3China
AY.8 (Delta)NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.469ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.62ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-3521.26Germany
BA.2.62ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.62NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.62NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.62NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.62NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.62NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used